The obesity epidemic in dogs has led to the exploration of weight-loss drugs specifically for pets. Up to 60% of dogs in the UK are estimated to be overweight or obese, creating a considerable market for such solutions. Okava, a biotech firm, is initiating trials for a drug mimicking the effects of popular human weight-loss drugs such as Ozempic, aiming for an implant version for dogs. Analysts predict a $10 billion market, with products potentially available by 2028 or 2029.
With up to 60 per cent of dogs in the UK estimated to be overweight or obese, the market for such drugs could be considerable.
Okava, a San Francisco-based bio-pharma company which specializes in pet health, is planning to run trials for a drug designed to mimic the effects of Ozempic.
The current market for such a product could be worth $10bn, and they hope to have a canine weight-loss drug available as early as 2028 or 2029.
Both human weight-loss drugs, Mounjaro and Ozempic, mimic a natural hormone called GLP-1, which regulates blood sugar and appetite.
Collection
[
|
...
]